Our research laboratory, embedded within the German Cancer Consortium (DKTK) and the Frankfurt Cancer Institute (FCI), is dedicated to unraveling the intricate mechanisms underlying lymphoma and leukemia biology, along with the vision to translate our research findings into clinical advancement. Our focus is the identification of drug targets and predictive biomarkers, the elucidation of therapy resistance mechanisms, and the development of innovative therapeutic approaches, including molecular and cellular therapies. Therefore, we combine deep mechanistic research with cutting-edge technologies such as mass-spectrometry-based proteomics, functional genomics and high-resolution imaging to study innovative tumor models and patient-derived tumors.

Our research is closely integrated into national (e.g. DKTK/NCT, Max-Planck) and international networks (e.g. NIH), emphasizing our interest in collaborative and international research. With a strong commitment to translational research and our proven track-record in translating lab research into the clinic, our ultimate goal is to improve patient outcome and quality of life.